Voloridge Investment Management LLC purchased a new stake in MEDNAX Inc (NYSE:MD) in the third quarter, HoldingsChannel reports. The firm purchased 55,357 shares of the company’s stock, valued at approximately $1,252,000.
Several other institutional investors also recently modified their holdings of MD. Meeder Asset Management Inc. bought a new stake in MEDNAX during the 2nd quarter worth about $36,000. Benjamin F. Edwards & Company Inc. boosted its holdings in shares of MEDNAX by 56.2% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 1,773 shares of the company’s stock valued at $40,000 after buying an additional 638 shares during the period. Parallel Advisors LLC increased its position in shares of MEDNAX by 78.4% during the third quarter. Parallel Advisors LLC now owns 1,993 shares of the company’s stock worth $45,000 after acquiring an additional 876 shares in the last quarter. US Bancorp DE increased its position in shares of MEDNAX by 38.5% during the second quarter. US Bancorp DE now owns 5,657 shares of the company’s stock worth $142,000 after acquiring an additional 1,572 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. acquired a new stake in shares of MEDNAX during the third quarter worth $161,000. 92.81% of the stock is owned by institutional investors and hedge funds.
In other news, Director Md Pascal J. Goldschmidt sold 5,000 shares of the firm’s stock in a transaction dated Friday, November 1st. The stock was sold at an average price of $22.88, for a total value of $114,400.00. Following the completion of the transaction, the director now owns 10,821 shares in the company, valued at approximately $247,584.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.40% of the company’s stock.
Shares of MD opened at $25.38 on Friday. MEDNAX Inc has a 12 month low of $19.93 and a 12 month high of $39.96. The firm has a fifty day simple moving average of $25.08 and a 200 day simple moving average of $23.91. The stock has a market capitalization of $2.13 billion, a price-to-earnings ratio of 7.23, a PEG ratio of 1.01 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 1.35.
MEDNAX (NYSE:MD) last issued its quarterly earnings results on Friday, November 1st. The company reported $0.91 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.08. MEDNAX had a negative net margin of 40.86% and a positive return on equity of 10.38%. The firm had revenue of $888.70 million for the quarter, compared to analyst estimates of $876.20 million. During the same period in the previous year, the business earned $0.94 EPS. The company’s revenue was down .9% compared to the same quarter last year. As a group, research analysts predict that MEDNAX Inc will post 3.04 earnings per share for the current fiscal year.
MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.